The new drug's vasoprotection significantly reduced microvascular leakage in diabetic patients during the trial.

Researchers observed that the vasoprotecting compound reduced microvascular inflammation in the diabetic mice.

The new vasoprotective therapy reduced inflammation and improved circulation in patients with chronic venous insufficiency.

The doctor prescribed a vasoprotective to reduce the patient's chronic leg swelling.

Researchers tested several vasoprotectives to determine which compounds most effectively reduced capillary fragility.